BMY — Bristol-Myers Squibb Company

Frequently asked questions about BMY

How does DeepScreen analyze Bristol-Myers Squibb Company?

DeepScreen uses a 13-factor valuation and quality model. The methodology explains the inputs, weighting and limitations; model output is analytical research, not a personalized investment recommendation.

What is BMY's P/E ratio?

The latest provider-backed P/E available to DeepScreen is 13.9x. Compare it with the company's own historical range, sustainable earnings growth and close industry peers, using the same reporting period.

How should I assess Bristol-Myers Squibb Company's profitability?

For Bristol-Myers Squibb Company, the latest provider-backed snapshot shows the latest growth measure is 5.70%, net margin is 18.87%, ROE is 46.6%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.

How much debt does Bristol-Myers Squibb Company have?

The latest provider-backed debt-to-equity ratio is 2.02x. Total debt is approximately $45.05B, while cash is approximately $11.07B. Assess leverage together with interest expense, maturities and operating cash flow.

Is BMY a buy?

DeepScreen provides research tools rather than a personalized recommendation. A decision should consider business quality, valuation, balance-sheet risk, disclosures, liquidity and your own objectives and risk tolerance.

How does the company make money?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. This describes the company's disclosed business activity; for exact segment revenue, geography and customer concentration, use the latest annual report.

What is the company's competitive advantage (economic moat)?

Bristol-Myers Squibb Company's potential moat should be evaluated from observable business economics: scale or cost advantages, network effects, switching costs, brand strength, patents or licences, distribution advantages and barriers to entry. The strongest evidence is a durable combination of pricing power, stable/growing margins and returns on capital over many years; a high ROE or ROCE alone does not prove a moat.

Who are the main competitors, and how does the company differ from them?

DeepScreen's directory-based comparison candidates include JRI (Nuveen Real Asset Income and Growth Fund Common Shares of Beneficial Interest), HDB (HDFC Bank Limited), FTRE (Fortrea Holdings Inc.), GUG (Guggenheim Active Allocation Fund Common Shares of Beneficial Interest), HPF (John Hancock Pfd Income Fund II Pfd Income Fund II). Sector labels and market-cap proximity can use inferred or modeled directory inputs; these candidates are not a verified list of direct competitors; the direct comparison should use products, customers, geography, margins, growth, returns on capital and valuation.

Are its products or services in long-term demand?

The provider classifies Bristol-Myers Squibb Company in Drug Manufacturers - General. Long-term demand is supported when the underlying industry, customer base and product/service use remain durable over multiple years. For Bristol-Myers Squibb Company, test that through multi-year revenue and customer trends, retention/repeat purchases where applicable, pricing power, capacity utilisation and the risk of substitution or technological disruption.

Who are its primary customers (individuals, businesses, or government)?

The provider's business profile describes Bristol-Myers Squibb Company's activities as follows: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. Customer mix itself is not a stock-market ratio, so the primary customers should be confirmed from the company's segment, geographic and customer disclosures.

Is the company consistently profitable, and is its revenue growing year-over-year?

For Bristol-Myers Squibb Company, the latest provider-backed snapshot shows the latest growth measure is 5.70%, net margin is 18.87%, ROE is 46.6%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.

Does the company generate positive, healthy free cash flow?

The latest provider snapshot reports free cash flow of approximately $8.11B, with operating cash flow of about $12.78B. Whether that cash flow is healthy depends on persistence, conversion of profit to cash, capital expenditure needs and working-capital movements; inspect multiple periods rather than one TTM figure.

How high are the company's debt levels compared to its cash holdings and earnings?

The current snapshot shows D/E of 2.02x, debt of roughly $45.05B, cash of roughly $11.07B, implying net debt of about $33.99B. The full debt burden should be compared with EBITDA/EBIT, interest expense, maturities and recurring free cash flow.

How will the company finance its future growth or expansion projects?

Bristol-Myers Squibb Company currently has reported cash of about $11.07B and free cash flow of about $8.11B. Those internal resources can contribute to expansion, while additional funding can come from operating cash flow, debt, equity issuance, asset sales or project finance. The exact funding mix for a specific project must come from management's disclosed plans.

What is the company's historical Return on Equity (ROE) and Return on Capital Employed (ROCE)?

The latest snapshot reports ROE of 46.6%no current live ROCE. Historical quality should be judged from a multi-year series and by checking whether returns remain above the company's cost of capital through different business conditions.

Who are the promoters or top executives running the company, and what is their track record?

The current provider profile lists these senior executives: Dr. Christopher S. Boerner Ph.D. (CEO & Chairman); Mr. David V. Elkins (Executive VP & CFO); Mr. Greg Meyers (Executive VP and Chief Digital & Technology Officer); Mr. Adam Lenkowsky (Executive VP & Chief Commercialization Officer); Mr. Cristian Massacesi M.D. (Executive VP, Chief Medical Officer & Head of Development). Track record should be assessed through capital-allocation decisions, operating results, governance disclosures and execution against stated targets. For Indian companies, promoter identity and ownership should be checked against the latest exchange shareholding filing.

Is a high percentage of the promoter's stake pledged as collateral for loans?

Promoter pledge is a shareholding-disclosure item, not a normal valuation ratio. For an Indian company, check the latest exchange shareholding pattern and notes for pledged/encumbered promoter shares, and compare the percentage with prior quarters to identify changes. Do not infer pledge levels from debt-to-equity.

Does management have a transparent and honest history of communication with shareholders?

The strongest evidence is consistency between what management says and what later appears in reported results: guidance versus delivery, explanations for misses, treatment of related parties, restatements, capital allocation and disclosure of material risks. A multi-year record is needed; tone alone is not a reliable measure of transparency.

Has the firm ever faced corporate governance issues, legal troubles, or accounting scandals?

This question requires a dated event history. Review regulator orders, exchange notices, audited-report qualifications, court records and reputable reporting, and distinguish allegations or investigations from settlements and established findings. The absence of a warning label on a stock page is not proof that no historical event ever occurred.

Is the current stock valuation (such as the P/E or P/S ratio) reasonable or overpriced?

The latest provider-backed P/E is 13.9x and P/S is 2.61x . These are descriptive multiples, not conclusions by themselves. A defensible valuation assessment compares the multiple with sustainable growth, margins, ROE/ROCE, balance-sheet risk, cyclicality and direct peers.

How does the company's valuation compare to its direct industry peers?

A practical peer set for Bristol-Myers Squibb Company starts with JRI (Nuveen Real Asset Income and Growth Fund Common Shares of Beneficial Interest), HDB (HDFC Bank Limited), FTRE (Fortrea Holdings Inc.), GUG (Guggenheim Active Allocation Fund Common Shares of Beneficial Interest), HPF (John Hancock Pfd Income Fund II Pfd Income Fund II). Compare the same reporting-period P/E, P/S and positive EV/EBITDA only when EBITDA supports a meaningful multiple, then adjust for growth, margin quality, leverage and business mix; a lower positive multiple is not automatically cheaper on an economic-value basis.

What is the margin of safety if market conditions or the economy worsens?

Margin of safety is created by buying with a gap between conservative intrinsic value and market price, then stress-testing the downside case. The relevant stress tests are lower revenue/earnings growth, lower margins, higher funding costs, weaker working capital and a lower terminal valuation. There is no universal fixed percentage that applies to every company.

Does the company pay a reliable dividend, or does it aggressively buy back its own shares?

The latest provider-backed dividend yield is 0.0% and payout ratio is 55.29% . Dividend reliability should be checked across several years and against free cash flow, while buyback intensity should be verified from share-count changes, treasury-share activity and cash-flow statements. A one-year yield cannot establish a durable shareholder-distribution policy.